., It is estimated that approximately 200,000 yellow fever infections occur annually, with several thousand deaths. But, the disease is grossly underreported and only about 5000 and 300 cases reported annually in Africa and South America, respectively (Monath, 2001 and E) and seven non-structural (NS1, NS2a. NS2b, NS3, NS4a, NS4b, and NS5) proteins.
and two short non-coding regions (3' and 5' NCRs) (Rice et ai., 1985; Hahn et ai.. 1987) .
Presently, seven yellow tever virus genotypes (tive in A trica and two in south America) are recognized wíthin a single serotype (Wang et ai., 1996; Mutebí et ai., 2001) .
The diagnosis of yellow fever, is based on the clinical symptoms and plus at least detection of specific IgM antibodies in unvaccinated persons (Kuno et ai., 1987) , virus isolation in animais ar cell cultures (Tesh, 1979; Tesh et ai., 2001) , detection of antigens by immunohistochemistry (Hall et ai., 1991) , and/or genome recovery by RT -PCR (Lanciotti et ai., 1992) .
Clinically, yellow fever occurring during an epidemic or in a patient having the classical signs of severe disease is relatively easy to diagnose. The problem is that only 10-20% of people The early phase of more severe forms shows similar symptoms/signs and is called the "period of infection". This phase lasts about three days. During this period, yellow fever virus can be detected in blood; therefore patients in this stage are infectious for mosquitoes. After this period, patients with abortive forms show rapid recovery, while those with severe forms have apparent improvement of symptoms that lasts several hours to one or two days and is known as "period of remission". This brief period is immediately followed by the "period of intoxication" that is characterized by low viremia or absence of it, return of high fever, and presence of jaundice, vomiting, epigastric pain, dehydration, hemorrhagic diathesis, prostration and renal failure. Other symptoms/signs commonly present at this stage include thrombocytopenia, albuminuria, tachycardia, hypotension, encephalopathic signs, and azotemia. The picture is easily recognized when, coffee-ground hematemesis, oligo-anuria and jaundice are evident.
About 50% of these patients have a fatal outcome. Other intermediate more or less severe forms have also been described (Serié et ai., 1968; Monath, 1988; Vasconcelos et ai., 1997; Monath, 2001; Vasconcelos, 2000) .
Yellow fever vírus is transmitted in different cycles in Africa and South America. In Africa, a third or intermediate cycle has been recognized in addition to the urban and jungle cycles (Digoutte et aI., 1995) . In South America, only two cycles (urban and jungle) has been recognized until now. In Africa, the vectors are mosquito species of the genus Aedes; in South America,
Haemagogus and Sabethes species are responsi,ble for the jungle cycle transmission (Monath. 1988 ).
The recent increases in distribution and density of Aedes aegypti in urban areas of the Americas with resulting epidemics of dengue fever and dengue hemorrhagic fever, brings again the concern of the re-urbanization of yellow fever (Mondet et ai., 1996; Vasconcelos et ai., 1999; Travassos da Rosa et ai., 2000) . It is worthy of note that the last urban epidemic in the Americas occurred in Rio de Janeiro in 1929-30, and the last case was reported in Port-of-Spain (Caribbean region) in 1954 (Nobre et ai., 1994; Dégallier et ai., 1996; Vasconcelos et ai" 1999) .
In South America, in the last two decades, yellow fever has been reported in Bolivia, Brazil, and Brazil almost 18%, Peru reported more than 50% of ali cases on the continent (Figure 2) . extensive Amazonian forest region in which jungle yellow fever is endemic and a coastal zone in which yellow fever does not currently occur (Robertson et ai., 1996; Vasconcelos et ai., 1997) .
The boundary between these two zones designated as pre-Amazon forest, and intermediate savanna and gallery forests may be affected by periodic expansions in epizootic activity (Mondet et ai., 1996; Vasconcelos et ai., 2001 h) .
In Brazil, the endemic area includes 12 states in the western two-thirds of the country inhabited by 29.3 million people. Beginning in the first quarter of 1998 and continuing to 2001, one of the largest epizootics in history has occurred, leading to the occurrence of 236 registered human cases of jungle yellow fever ; 1 05 of them or 44.5% had a fatal outcome ( Considering the annual disease occurrence of yellow fever and actual figures of Aedes aegypti indexes in the South America, the risk of re-urbanization raises the question of massive use of yellow fever vaccine to prevent it. Thus, in the last four years (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) , Brazil has used more than 60 million doses of the1700 vaccine especially in endemic and transitional yellow fever zones ( Figure 5 ). This massive use, resulted in the appearance of several serious adverse events, including deaths due the vaccine (Vasconcelos et ai., 2001c; Galler et ai., 2001) . In consequence, Brazilian authorities reviewed the policy for vaccine utilization and yellow fever vaccination is now only recommended to people living in the high risk areas (endemic and transitional zones), and for those that are travelling or will travei to these areas, focusing on tourists, agricultural workers, and migrants, the groups most affected by the disease (Vasconcelos et ai., 2001 b) .
To conclude, we suggest that other South American countries establish national policies for the use of yellow fever vaccine. But, it is important to emphasize, that the most important step is trying to control the Aedes aegypti levels. This is the best way to avoid re-urbanization of yellow fever and to prevent the lost of many human lives. 
